WO2023014296A3 - Molecular glue and sall4 degrader - Google Patents
Molecular glue and sall4 degrader Download PDFInfo
- Publication number
- WO2023014296A3 WO2023014296A3 PCT/SG2022/050551 SG2022050551W WO2023014296A3 WO 2023014296 A3 WO2023014296 A3 WO 2023014296A3 SG 2022050551 W SG2022050551 W SG 2022050551W WO 2023014296 A3 WO2023014296 A3 WO 2023014296A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sall4
- degrader
- molecular glue
- cancer
- compounds
- Prior art date
Links
- 239000001064 degrader Substances 0.000 title 1
- 239000003292 glue Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 abstract 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 abstract 1
- 201000007270 liver cancer Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Provided is the use of compounds of Formula I, as well as certain specific compounds, or a pharmaceutically acceptable salt, solvate or derivative thereof, in the preparation of a medicament to treat cancer, such as liver cancer (e.g. hepatocellular carcinoma) and lung cancer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22853619.9A EP4380557A2 (en) | 2021-08-02 | 2022-08-02 | Molecular glue and sall4 degrader |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163228240P | 2021-08-02 | 2021-08-02 | |
US63/228,240 | 2021-08-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2023014296A2 WO2023014296A2 (en) | 2023-02-09 |
WO2023014296A3 true WO2023014296A3 (en) | 2023-04-27 |
Family
ID=85156467
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SG2022/050551 WO2023014296A2 (en) | 2021-08-02 | 2022-08-02 | Molecular glue and sall4 degrader |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP4380557A2 (en) |
WO (1) | WO2023014296A2 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130156795A1 (en) * | 2009-09-01 | 2013-06-20 | Antonio Iavarone | Methods for inhibition of cell proliferation, synergistic transcription modules and uses thereof |
US20150210717A1 (en) * | 2012-09-13 | 2015-07-30 | Baden-Württemberg Stiftung Gmbh | Specific inhibitors of protein p21 as therapeutic agents |
CN106496108A (en) * | 2016-11-01 | 2017-03-15 | 上海应用技术大学 | There is amides compound and its application of anti-tumor activity |
WO2019070943A1 (en) * | 2017-10-04 | 2019-04-11 | Dana-Farber Cancer Institute, Inc. | Small molecule inhibition of transcription factor sall4 and uses thereof |
WO2020123675A1 (en) * | 2018-12-11 | 2020-06-18 | Duke University | Compositions and methods for the treatment of cancer |
WO2020242376A1 (en) * | 2019-05-28 | 2020-12-03 | Agency For Science, Technology And Research | Method of treating a sall4-expressing cancer |
-
2022
- 2022-08-02 WO PCT/SG2022/050551 patent/WO2023014296A2/en active Application Filing
- 2022-08-02 EP EP22853619.9A patent/EP4380557A2/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130156795A1 (en) * | 2009-09-01 | 2013-06-20 | Antonio Iavarone | Methods for inhibition of cell proliferation, synergistic transcription modules and uses thereof |
US20150210717A1 (en) * | 2012-09-13 | 2015-07-30 | Baden-Württemberg Stiftung Gmbh | Specific inhibitors of protein p21 as therapeutic agents |
CN106496108A (en) * | 2016-11-01 | 2017-03-15 | 上海应用技术大学 | There is amides compound and its application of anti-tumor activity |
WO2019070943A1 (en) * | 2017-10-04 | 2019-04-11 | Dana-Farber Cancer Institute, Inc. | Small molecule inhibition of transcription factor sall4 and uses thereof |
WO2020123675A1 (en) * | 2018-12-11 | 2020-06-18 | Duke University | Compositions and methods for the treatment of cancer |
WO2020242376A1 (en) * | 2019-05-28 | 2020-12-03 | Agency For Science, Technology And Research | Method of treating a sall4-expressing cancer |
Non-Patent Citations (5)
Title |
---|
HU, W.P. ET AL.: "Synthesis and biological evaluation of thiobenzanilides as anticancer agents", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 16, no. 9, 6 March 2008 (2008-03-06), pages 5295 - 5302, XP022647320, [retrieved on 20230328], DOI: 10.1016/J.BMC. 2008.03.00 3 * |
KENLAN, D.E. ET AL.: "Fluorinated N,N'-Diarylureas As Novel Therapeutic Agents Against Cancer Stem Cells", MOLECULAR CANCER THERAPEUTICS, vol. 16, no. 5, 2 May 2017 (2017-05-02), pages 831 - 837, XP055876037, [retrieved on 20230328], DOI: 10.1158/1535-7163.MCT-15-0634 * |
XU TIAN, ZHANG JIFA, YANG CHENGCAN, PLUTA RYSZARD, WANG GUAN, YE TINGHONG, OUYANG LIANG: "Identification and optimization of 3-bromo-N’-(4-hydroxybenzylidene)-4-methylbenzohydrazide derivatives as mTOR inhibitors that induce autophagic cell death and apoptosis in triple-negative breast cancer", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 219, 1 July 2021 (2021-07-01), AMSTERDAM, NL , pages 113424, XP093064991, ISSN: 0223-5234, DOI: 10.1016/j.ejmech.2021.113424 * |
ZHANG YUAN, MENG XIN, TANG HAIKANG, CHENG MINGHUI, YANG FUJUN, XU WENQING: "Design, synthesis, and biological evaluation of novel substituted thiourea derivatives as potential anticancer agents for NSCLC by blocking K-Ras protein-effectors interactions", JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, INFORMA HEALTHCARE, GB, vol. 35, no. 1, 1 January 2020 (2020-01-01), GB , pages 344 - 353, XP093064990, ISSN: 1475-6366, DOI: 10.1080/14756366.2019.1702653 * |
ZHU, Z.W. ET AL.: "Synthesis and antiproliferative activities against Hep-G2 of salicylanide derivatives: potent inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase", JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, vol. 26, no. 1, 28 June 2010 (2010-06-28), pages 37 - 45, XP055663729, [retrieved on 20230328], DOI: 10.3109/14756361003671060 * |
Also Published As
Publication number | Publication date |
---|---|
WO2023014296A2 (en) | 2023-02-09 |
EP4380557A2 (en) | 2024-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SA520420033B1 (en) | Pharmaceutical compounds | |
WO2020113213A3 (en) | Cyclic pantetheine derivatives and uses thereof | |
CY1113846T1 (en) | PYRIMIDINIS DERIVATIVES FOR THE THERAPEUTIC TREATMENT OF ASTHMA, COPD, ALLERGIKIS RINITIDAS, ALLERGIKIS EPIPEFYKITIDAS, ATOPIKIS DERMATITIDAS, CANCER, HEPATITIS B, HEPATITIS C, HIV, HPV, bacterial infections and DERMATOSIS | |
MX2009006742A (en) | Novel compounds. | |
MX2012001654A (en) | Methods of using c-met modulators. | |
EA201100971A1 (en) | DERIVATIVES OF PYRIMIDININDOL FOR THE TREATMENT OF MALIGNANT NORMALIZATION | |
BR112012003578A8 (en) | COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT, SULFATE SALT, PHARMACEUTICAL COMPOSITION, METHOD FOR TREATING A VIRAL INFECTION, AND, USE OF A COMPOUND OR SALT | |
WO2016133903A3 (en) | Combination therapy for cancer treatment | |
TW200700093A (en) | Pharmaceutical composition for the treatment of cancer | |
DE50311898D1 (en) | FREDERICAMYCIN DERIVATIVES AS A MEDICAMENT FOR TUMOR TREATMENT | |
EA201001669A1 (en) | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | |
GEP20156289B (en) | New aminopyrazoloquinazolines | |
EP4342473A3 (en) | Compounds useful in hiv therapy | |
TNSN07419A1 (en) | Methods for treating drug resistant cancer | |
PH12021550713A1 (en) | Medicament for the treatment of chronic cough | |
MX2022015554A (en) | Small molecule modulators of il-17. | |
PH12021550443A1 (en) | Pyridazinones and methods of use thereof | |
TNSN07294A1 (en) | Treatment of metastasized tumors | |
MX2021008010A (en) | Compositions and methods to treat non-alcoholic fatty liver diseases (nafld). | |
MX2024001777A (en) | Sulfonamide derivative, preparation method therefor and medical use thereof. | |
AU2019375825A8 (en) | Macrocyclic tyrosine kinase inhibitor and uses thereof | |
AU2020231934A8 (en) | Compounds useful in HIV therapy | |
UA96969C2 (en) | Acylaminopyrazoles as fgfr inhibitors | |
WO2022261250A8 (en) | Therapeutics for the degradation of mutant braf | |
MX2021015447A (en) | Methods of treating cancer by targeting cold tumors. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 11202400685X Country of ref document: SG |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022853619 Country of ref document: EP Effective date: 20240304 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22853619 Country of ref document: EP Kind code of ref document: A2 |